UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 277

Sortiert nach

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Journal of clinical oncology, 2010-07, Vol.28 (20), p.3323-3329

2010

Link zum Volltext

Verfügbarkeit prüfen

Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial

Journal of clinical oncology, 2005-12, Vol.23 (34), p.8802-8811

2005

Link zum Volltext

Verfügbarkeit prüfen

The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients

Clinical cancer research, 2004-07, Vol.10 (13), p.4420-4426

2004

Link zum Volltext

Verfügbarkeit prüfen

Randomized Trial of Two or Five Computed Tomography Scans in the Surveillance of Patients With Stage I Nonseminomatous Germ Cell Tumors of the Testis: Medical Research Council Trial TE08, ISRCTN56475197—The National Cancer Research Institute Testis Cancer Clinical Studies Group

Journal of clinical oncology, 2007-04, Vol.25 (11), p.1310-1315

2007

Link zum Volltext

Verfügbarkeit prüfen

Role of Docetaxel in the Treatment of Newly Diagnosed Advanced Ovarian Cancer

Journal of clinical oncology, 2003-05, Vol.21 (10 suppl), p.136s-144

Vasey, Paul A

2003

Link zum Volltext

Verfügbarkeit prüfen

Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

JNCI : Journal of the National Cancer Institute, 2004-11, Vol.96 (22), p.1682-1691

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

Investigational new drugs, 2013-02, Vol.31 (1), p.126-135

2013

Link zum Volltext

Verfügbarkeit prüfen

Part II: Testicular cancer—management of advanced disease

The lancet oncology, 2003-12, Vol.4 (12), p.738-747

2003

Link zum Volltext

Verfügbarkeit prüfen

Part I: Testicular cancer—management of early disease

The lancet oncology, 2003-12, Vol.4 (12), p.730-737

2003

Link zum Volltext

Verfügbarkeit prüfen

Cell cycle arrests and radiosensitivity of human tumor cell lines : dependence on wild-type p53 for radiosensitivity

Cancer research (Chicago, Ill.), 1994-07, Vol.54 (14), p.3718-3722

1994

Link zum Volltext

Verfügbarkeit prüfen

Management of recurrent epithelial ovarian carcinoma

Australian & New Zealand journal of obstetrics & gynaecology, 2005-08, Vol.45 (4), p.269-277

VASEY, Paul A.

2005

Link zum Volltext

Verfügbarkeit prüfen

Microtubule Stabilization in the Treatment of Solid Tumors: Role of the Taxanes

The oncologist (Dayton, Ohio), 2004-01, Vol.9 (S2), p.1-2

Vasey, Paul A.

2004

Link zum Volltext

Verfügbarkeit prüfen

Intraperitoneal chemotherapy for epithelial ovarian carcinoma

Future oncology (London, England), 2005-06, Vol.1 (3), p.289-292

Vasey, Paul A

2005

Link zum Volltext

Verfügbarkeit prüfen

Progress in the management of gynecologic cancer: consensus summary statement

Journal of clinical oncology, 2003-05, Vol.21 (10 Suppl), p.129s-132

2003

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel in ovarian cancer: Phase III perspectives and future development

Seminars in oncology, 2002-06, Vol.29 (3), p.22-27

2002

Link zum Volltext

Verfügbarkeit prüfen

The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer

International journal of cancer, 2012-08, Vol.131 (4), p.885-890

2012

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy for renal carcinoma: theoretical basis and current standard of care

British journal of clinical pharmacology, 2000-12, Vol.50 (6), p.521-529

Vasey, Paul A.

2000

Link zum Volltext

Verfügbarkeit prüfen

Concurrent presentation of Stage I teratoma and Stage I renal cell cancer

Acta oncologica, 2005-03, Vol.44 (2), p.174-176

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin] : First member of a new class of chemotherapeutic agents-drug-polymer conjugates

Clinical cancer research, 1999, Vol.5 (1), p.83-94

1999

Link zum Volltext

Verfügbarkeit prüfen

Surgical management in patients with pancreatic cancer: a Queensland perspective

ANZ journal of surgery, 2013-11, Vol.83 (11), p.859-864

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762)

Cancer research (Chicago, Ill.), 1995-05, Vol.55 (10), p.2090-2096

1995

Link zum Volltext

Verfügbarkeit prüfen

“Dose dense” chemotherapy in ovarian cancer

International journal of gynecological cancer, 2005-11, Vol.15 (s3), p.226-232

VASEY, P.A.

2005

Link zum Volltext

Verfügbarkeit prüfen

Part I: Testicular cancer-management of early disease

The lancet oncology, 2003-12, Vol.4 (12), p.738

2003

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer

Journal of clinical oncology, 1999-07, Vol.17 (7), p.2069-2080

1999

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance

Molecular pharmacology, 1996-12, Vol.50 (6), p.1536-1540

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 277

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(248)
Mit Volltextzugriff
(265)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial

The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients

Randomized Trial of Two or Five Computed Tomography Scans in the Surveillance of Patients With Stage I Nonseminomatous Germ Cell Tumors of the Testis: Medical Research Council Trial TE08, ISRCTN56475197—The National Cancer Research Institute Testis Cancer Clinical Studies Group

Role of Docetaxel in the Treatment of Newly Diagnosed Advanced Ovarian Cancer

Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

Part II: Testicular cancer—management of advanced disease

Part I: Testicular cancer—management of early disease

Cell cycle arrests and radiosensitivity of human tumor cell lines : dependence on wild-type p53 for radiosensitivity

Management of recurrent epithelial ovarian carcinoma

Microtubule Stabilization in the Treatment of Solid Tumors: Role of the Taxanes

Intraperitoneal chemotherapy for epithelial ovarian carcinoma

Progress in the management of gynecologic cancer: consensus summary statement

Docetaxel in ovarian cancer: Phase III perspectives and future development

The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer

Immunotherapy for renal carcinoma: theoretical basis and current standard of care

Concurrent presentation of Stage I teratoma and Stage I renal cell cancer

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin] : First member of a new class of chemotherapeutic agents-drug-polymer conjugates

Surgical management in patients with pancreatic cancer: a Queensland perspective

Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762)

“Dose dense” chemotherapy in ovarian cancer

Part I: Testicular cancer-management of early disease

Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer

Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance

Suchergebnisse filtern